PE20030417A1 - Derivados de urea como antagonistas del receptor vainilloide - Google Patents
Derivados de urea como antagonistas del receptor vainilloideInfo
- Publication number
- PE20030417A1 PE20030417A1 PE2002000895A PE2002000895A PE20030417A1 PE 20030417 A1 PE20030417 A1 PE 20030417A1 PE 2002000895 A PE2002000895 A PE 2002000895A PE 2002000895 A PE2002000895 A PE 2002000895A PE 20030417 A1 PE20030417 A1 PE 20030417A1
- Authority
- PE
- Peru
- Prior art keywords
- urea
- alkyl
- pyridyl
- trifluoromethyl
- aryl
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 2
- -1 POLYMETHYLENE CHAIN Polymers 0.000 abstract 6
- 239000004202 carbamide Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- DWYHJOLGUSRZSO-UHFFFAOYSA-N 1-phenyl-3-(1-phenylpyrrolidin-3-yl)urea Chemical compound C=1C=CC=CC=1NC(=O)NC(C1)CCN1C1=CC=CC=C1 DWYHJOLGUSRZSO-UHFFFAOYSA-N 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000003349 osteoarthritic effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A DERIVADOS DE UREA DE FORMULA I DONDE P Y P' SON ARILO, HETEROARILO; R1 Y R2 SON H, HALOGENO, ALQUILO, ALCOXI, CICLOALQUILO, ARALQUILO, ARALCOXI, CICLOALQUILALQUILO, CN, NO2, OH, OCF3, CF3, ENTRE OTROS; R4 Y R5 SON H, ALQUILO O JUNTOS FORMAN UN ANILLO AZACICLOALCANO C3-C6, (2-OXO)AZACICLOALCANO C3-C6, CADENA POLIMETILENO C5-C8; Z ES O, S, NR7; R6 ES ALQUILO, ARILO, R7 ES H, ALQUILO, ARILO; m ES 1-2; n ES 0-3; p Y q SON 0-4; r ES 1-3; s ES 0-2; x ES 0-6; EXCEPTO LOS COMPUESTOS 1-(1-FENIL-3-PIRROLIDINIL)-3-FENIL-UREA; 1-(1-FENIL-3-PIRROLIDINIL)-3-(4-METOXIFENIL)-UREA, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(2-BROMOFENIL)-N'-[(®-1-(5-TRIFLUOROMETIL-2-PIRIDIL)PIRROLIDIN-3-IL)]UREA; N-(ISOQUINOL-5-IL)-N'-[(®-1-(5-TRIFLUOROMETIL-2-PIRIDIL)-PIRROLIDIN-3-IL)]UREA; (+/-)-N-(ISOQUINOL-5-IL)-N'-[(1-(5-TRIFLUOROMETIL-2-PIRIDIL)-PIPERIDIN-3-IL)]UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR VAINILLOIDE Y PUEDEN SER UTILES PARA EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICO, POST OPERATORIO, ARTRITICO POST REUMATOIDE, OSTEOARTRITICO, MIGRANAS, NEUROPATIAS, SINDROME DEL CANAL CARPIANO, NEUROPATIA DIABETICA
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0122156A GB0122156D0 (en) | 2001-09-13 | 2001-09-13 | Novel compounds |
| GB0130505A GB0130505D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
| GB0130547A GB0130547D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
| GB0130503A GB0130503D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030417A1 true PE20030417A1 (es) | 2003-08-06 |
Family
ID=27447989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000895A PE20030417A1 (es) | 2001-09-13 | 2002-09-11 | Derivados de urea como antagonistas del receptor vainilloide |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8063078B2 (es) |
| EP (3) | EP1425277B8 (es) |
| JP (2) | JP4463552B2 (es) |
| KR (3) | KR101063679B1 (es) |
| CN (1) | CN1247568C (es) |
| AP (1) | AP1818A (es) |
| AR (1) | AR038786A1 (es) |
| AT (1) | ATE420083T1 (es) |
| AU (1) | AU2002329397B2 (es) |
| BR (1) | BR0212468A (es) |
| CA (1) | CA2458632C (es) |
| CY (1) | CY1109449T1 (es) |
| DE (1) | DE60230773D1 (es) |
| DK (1) | DK1425277T3 (es) |
| EA (1) | EA007731B1 (es) |
| ES (1) | ES2316607T3 (es) |
| HU (1) | HUP0401923A3 (es) |
| IL (2) | IL160755A0 (es) |
| MA (1) | MA26216A1 (es) |
| MX (1) | MXPA04002379A (es) |
| MY (1) | MY138086A (es) |
| NO (3) | NO327009B1 (es) |
| NZ (1) | NZ531137A (es) |
| OA (1) | OA12659A (es) |
| PE (1) | PE20030417A1 (es) |
| PL (1) | PL213639B1 (es) |
| PT (1) | PT1425277E (es) |
| SI (1) | SI1425277T1 (es) |
| TW (1) | TWI283665B (es) |
| UY (1) | UY27446A1 (es) |
| WO (1) | WO2003022809A2 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY138086A (en) | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
| ATE465993T1 (de) | 2002-02-01 | 2010-05-15 | Euro Celtique Sa | 2-piperazinpyridine für die schmerzbehandlung |
| EP1478363B1 (en) * | 2002-02-20 | 2009-01-14 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| EA200500114A1 (ru) | 2002-06-28 | 2005-06-30 | Еуро-Селтик, С. А. | Терапевтические агенты, используемые для лечения боли |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| GB0221157D0 (en) * | 2002-09-12 | 2002-10-23 | Glaxo Group Ltd | Novel treatment |
| WO2004024710A1 (en) * | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| PT1569896E (pt) | 2002-12-06 | 2007-11-15 | Xention Ltd | Derivados de tetra-hidronaftaleno |
| GB0229808D0 (en) * | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compositions |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| ES2330107T3 (es) * | 2003-03-06 | 2009-12-04 | Glaxo Group Limited | Derivados de urea heterociclicos para el tratamiento del dolor. |
| JP2006519806A (ja) * | 2003-03-07 | 2006-08-31 | グラクソ グループ リミテッド | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 |
| GB0305426D0 (en) * | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| EP1627869B1 (en) | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| GB0319151D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| GB0319150D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| CA2540647C (en) * | 2003-10-01 | 2012-07-10 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
| WO2005035471A1 (ja) | 2003-10-14 | 2005-04-21 | Ajinomoto Co., Inc. | エーテル誘導体 |
| JP2007509846A (ja) * | 2003-10-15 | 2007-04-19 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | テトラヒドロ−ナフタレンおよび尿素誘導体 |
| EP1685112B1 (en) | 2003-11-08 | 2011-07-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydro-quinolinylurea derivatives as vr1 antagonists |
| EP1736465A4 (en) * | 2004-03-31 | 2009-06-17 | Ajinomoto Kk | ANILINE DERIVATIVES |
| CA2584502A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | 2-methylpropanamides and their use as pharmaceuticals |
| JP2008508190A (ja) | 2004-07-19 | 2008-03-21 | ノボ ノルディスク アクティーゼルスカブ | 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害 |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| WO2006098554A1 (en) * | 2005-03-16 | 2006-09-21 | Amorepacific Corporation | Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| EP1889830A1 (en) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| PL2054411T3 (pl) * | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| TW200824687A (en) | 2006-08-25 | 2008-06-16 | Abbott Lab | Compounds that inhibit TRPV1 and uses thereof |
| EP2450346A1 (en) | 2006-12-20 | 2012-05-09 | Abbott Laboratories | Antagonists of the TRPV1 receptor and uses thereof |
| WO2009117626A2 (en) | 2008-03-20 | 2009-09-24 | Abbott Laboratories | Methods for making central nervous system agents that are trpv1 antagonists |
| EP2264031B1 (en) | 2008-04-18 | 2015-04-15 | Daewoong Pharmaceutical Co., Ltd. | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
| CN102089277B (zh) * | 2008-05-07 | 2014-02-12 | 大日本住友制药株式会社 | 环状胺-1-甲酸酯衍生物及含有其的药物组合物 |
| US20110200646A1 (en) * | 2008-09-02 | 2011-08-18 | Charanjit Bountra | The TRPVL Antagonists SB-795498 For Treating Rhinitis |
| WO2010026128A1 (en) * | 2008-09-02 | 2010-03-11 | Glaxo Group Limited | N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis |
| JP2013028536A (ja) * | 2009-11-11 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
| WO2012045729A1 (en) | 2010-10-05 | 2012-04-12 | Glaxo Group Limited | Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists |
| KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| WO2012072512A1 (en) | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| GB201101517D0 (en) * | 2011-01-28 | 2011-03-16 | Proximagen Ltd | Receptor antagonists |
| EP2697221A1 (en) | 2011-04-11 | 2014-02-19 | Glaxo Group Limited | N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3424760A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| US3424761A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
| DE68918991T2 (de) | 1988-06-17 | 1995-04-27 | Procter & Gamble | Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion. |
| HU206082B (en) | 1988-12-23 | 1992-08-28 | Sandoz Ag | Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds |
| CA2017383A1 (en) | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
| WO1992009285A1 (en) | 1990-11-27 | 1992-06-11 | The Procter & Gamble Company | Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections |
| US5149704A (en) | 1991-05-03 | 1992-09-22 | Abbott Laboratories | Platelet activating antagonists |
| CA2197364A1 (en) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
| WO1999000128A1 (en) * | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
| WO1999000121A1 (en) * | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
| JP2000080085A (ja) | 1997-09-01 | 2000-03-21 | Kyorin Pharmaceut Co Ltd | ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法 |
| CN1210254C (zh) | 1999-02-22 | 2005-07-13 | 株式会社太平洋 | 作为有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用 |
| DK1165516T3 (da) | 1999-03-12 | 2005-01-31 | Boehringer Ingelheim Pharma | Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler |
| EP1220836A2 (en) * | 1999-10-15 | 2002-07-10 | Bristol-Myers Squibb Pharma Company | Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| MXPA03000458A (es) | 2000-07-20 | 2004-06-02 | Neurogen Corp | Ligandos receptores de capsaicina. |
| WO2002016318A1 (en) | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| WO2002016317A1 (en) | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same |
| AU2001280230A1 (en) | 2000-08-21 | 2002-03-04 | Pacific Corporation | Novel thiourea compounds and the pharmaceutical compositions containing the same |
| JP2002080073A (ja) | 2000-09-07 | 2002-03-19 | Kyokuto Kobunshi Kk | 電子レンジ用自動開孔袋 |
| JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| GB0110901D0 (en) | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
| MY138086A (en) * | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
| CN1678586A (zh) * | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
| WO2004024710A1 (en) | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| GB0229808D0 (en) | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compositions |
| CA2563494A1 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Urea derivatives as antagonists of the vanilloid receptor (vr1) |
-
2002
- 2002-09-11 MY MYPI20023391A patent/MY138086A/en unknown
- 2002-09-11 TW TW091120671A patent/TWI283665B/zh not_active IP Right Cessation
- 2002-09-11 PE PE2002000895A patent/PE20030417A1/es not_active Application Discontinuation
- 2002-09-12 UY UY27446A patent/UY27446A1/es not_active Application Discontinuation
- 2002-09-12 AR ARP020103454A patent/AR038786A1/es active IP Right Grant
- 2002-09-13 AT AT02765023T patent/ATE420083T1/de active
- 2002-09-13 HU HU0401923A patent/HUP0401923A3/hu unknown
- 2002-09-13 NZ NZ531137A patent/NZ531137A/en not_active IP Right Cessation
- 2002-09-13 KR KR1020047003680A patent/KR101063679B1/ko not_active Expired - Fee Related
- 2002-09-13 SI SI200230792T patent/SI1425277T1/sl unknown
- 2002-09-13 ES ES02765023T patent/ES2316607T3/es not_active Expired - Lifetime
- 2002-09-13 KR KR1020097003812A patent/KR100955967B1/ko not_active Expired - Fee Related
- 2002-09-13 OA OA1200400070A patent/OA12659A/en unknown
- 2002-09-13 KR KR1020107014626A patent/KR20100082390A/ko not_active Ceased
- 2002-09-13 EP EP02765023A patent/EP1425277B8/en not_active Expired - Lifetime
- 2002-09-13 WO PCT/GB2002/004206 patent/WO2003022809A2/en not_active Ceased
- 2002-09-13 JP JP2003526885A patent/JP4463552B2/ja not_active Expired - Fee Related
- 2002-09-13 PL PL369026A patent/PL213639B1/pl not_active IP Right Cessation
- 2002-09-13 US US10/489,277 patent/US8063078B2/en not_active Expired - Fee Related
- 2002-09-13 EP EP10179466A patent/EP2298757A3/en not_active Withdrawn
- 2002-09-13 BR BR0212468-8A patent/BR0212468A/pt not_active IP Right Cessation
- 2002-09-13 EA EA200400432A patent/EA007731B1/ru not_active IP Right Cessation
- 2002-09-13 DK DK02765023T patent/DK1425277T3/da active
- 2002-09-13 AU AU2002329397A patent/AU2002329397B2/en not_active Ceased
- 2002-09-13 CA CA2458632A patent/CA2458632C/en not_active Expired - Fee Related
- 2002-09-13 DE DE60230773T patent/DE60230773D1/de not_active Expired - Lifetime
- 2002-09-13 PT PT02765023T patent/PT1425277E/pt unknown
- 2002-09-13 AP APAP/P/2004/002982A patent/AP1818A/en active
- 2002-09-13 MX MXPA04002379A patent/MXPA04002379A/es active IP Right Grant
- 2002-09-13 EP EP08172882A patent/EP2036902A3/en not_active Withdrawn
- 2002-09-13 IL IL16075502A patent/IL160755A0/xx unknown
- 2002-09-13 CN CNB028177177A patent/CN1247568C/zh not_active Expired - Fee Related
-
2004
- 2004-03-04 IL IL160755A patent/IL160755A/en not_active IP Right Cessation
- 2004-03-10 NO NO20041003A patent/NO327009B1/no not_active IP Right Cessation
- 2004-03-12 MA MA27573A patent/MA26216A1/fr unknown
-
2008
- 2008-12-04 NO NO20085078A patent/NO20085078L/no unknown
- 2008-12-04 NO NO20085077A patent/NO20085077L/no not_active Application Discontinuation
-
2009
- 2009-03-19 CY CY20091100306T patent/CY1109449T1/el unknown
- 2009-12-08 JP JP2009278584A patent/JP2010100632A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030417A1 (es) | Derivados de urea como antagonistas del receptor vainilloide | |
| PE20220341A1 (es) | Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf | |
| RU2007148217A (ru) | Получение производных n-фенил-2-пиримидинамина | |
| PE20051046A1 (es) | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| PE20020354A1 (es) | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) | |
| PE20050896A1 (es) | Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos | |
| ATE123771T1 (de) | Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung. | |
| ATE449083T1 (de) | Chinazolin-derivate und ihre verwendung als arzneimittel | |
| AR027402A1 (es) | Derivados de pirimidina. | |
| RU2004120553A (ru) | Производные никотинамида, полезные в качестве р38-ингибиторов | |
| AR042024A1 (es) | Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
| PE20030593A1 (es) | DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR062299A1 (es) | Derivados de bencimidazol | |
| PE20041061A1 (es) | Imidazol-4-il-etinil-piridina | |
| PE20091387A1 (es) | Proceso de preparacion de derivados de tetrazol-5-il-bifenilo | |
| PE20070113A1 (es) | Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb | |
| MX9708147A (es) | Compuestos de bencimidazol y su uso como moduladores del complejo receptor de gabaa. | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |